Pulmonary embolism

Thorax

Volumn 53, Issue 8, 1998, Pages 698-702

  Laffan, Michael ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING; DEEP VEIN THROMBOSIS; FIBRINOLYSIS; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOPHILIA; DISEASE PREDISPOSITION; DOMINANT GENE; GENETICS; MUTATION; THROMBOPHLEBITIS;

ANTITHROMBIN; PROTEIN C; PROTEIN S;

ANTITHROMBINS; DISEASE SUSCEPTIBILITY; GENES, DOMINANT; HUMANS; MUTATION; PROTEIN C; PROTEIN S; PULMONARY EMBOLISM; THROMBOPHILIA; THROMBOPHLEBITIS;

EID: 0031847385     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.8.698     Document Type: Review

References (50)

1. Huisman MV, Buller HR, ten CJ, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989;95:498-502.
2. Dorfman GS, Cronan JJ, Tupper TB, et al. Occult pulmonary embolism: a common occurrence in deep venous thrombosis. Am J Roentgenol 1987;148:263-6.
3. Kruit WH, de BA, Sing AK, van RF. The significance of venography in the management of patients with clinically suspected pulmonary embolism. J Intern Med 1991;230: 333-9.
4. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983;98:891-9.
5. Doyle DJ, Turpie AG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. Ann Intern Med 1987;107:441-5.
6. van der Meer F, Koster T, Vandenbroucke JP, et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78:631-5.
7. Heijboer H, Brandjes DP, Buller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990;323: 1512-6.
8. Malm J, Laurell M, Nilsson IM, et al. Thromboembolic disease: critical evaluation of laboratory investigation. Thromb Haemost 1992;68:7-13.
9. Ridker P, Hennekens C, Lindpainter K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thromboembolism in apparently healthy men. N Engl J Med 1995,332: 912-7.
10. Lane DA, Mannucci P, Bauer K, et al. Inherited thrombophilia: part 1. Thromb Haemost 1996;76:651-62.
11. Lane DA, Mannucci P, Bauer K, et al. Inherited thrombophilia: part 2. Thromb Haemost 1996;76:824-34.
12. Olds RJ, Lane DA, Mille B, et al. Antithrombin: the principal inhibitor of thrombin. Semin Thromb Hemost 1994;20: 353-72.
13. Stearns KD, Kurosawa S, Mollica JS, et al. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996;93:10212-6.
14. Simmons RE, Zoller BHI, Dahlback B, et al. Genetic and phenotypic analysis of a large (122 member) protein S deficient kindred provides an explanation for the coexistence of type I and type III plasma phenotypes. Blood 1997;89:4364-70
15. Faioni EM, Franchi F, Asti D, et al. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haeniost 1993;70:1067-71.
16. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
17. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
18. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
19. Takamiya O, Ishida F, Kodaira H, et al. APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995;74:996.
20. Koster T, Rosendaal FR, de RH, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
21. Allaart CF, Poort SR, Rosendaal FR, et al. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993;341:134-8.
22. Bovill EG, Bauer KA, Dickerman JD, et al. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989;73:712-7.
23. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C or protein S deficiency. Aterioscler Thromb Vasc Biol 1996;16:742-8.
24. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
25. Koster T, Blann A, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995;345:152-5.
26. O'Donnell J, Tuddenham EGD, Manning R, et al. High prevalence of elevated factor VIIIc levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997;77:825-8.
27. Poort S, Rosendaal F, Reitsma P, et al. A common genetic variation in the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88: 3698-703.
28. den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?. Lancet 1995;345:882-5.
29. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995;10: 111-3.
30. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995;85:330-6.
31. Ireland H, Kunz O, Kyriakoulis K, et al. Thrombomodulin gene mutations associated with myocardial infarction. Circulation 1997;96:15-8.
32. Norlund L, Holm J, Zoller B, et al. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost 1997;77:248-51.
33. Goldhaber SZ, Grodstein F, Stamplfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642-5.
34. Juhan VI, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987;57:67-72.
35. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-45.
36. Ridker PM, Vaughan DE, Stampfer MJ, et al. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992;85:1822-7.
37. Dolan G, Greaves M, Cooper P, et al. Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. Br J Haematol 1988;70:417-21.
38. Koeleman BP, Reitsma PH, Allaart CF, et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994;84:1031-5.
39. Zoller B, Berntsdotter A, Garcia dFP, et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995;85:3518-23.
40. van Boven HA, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FVR506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996;75:417-21.
41. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden: effect on thrombosis. N Engl J Med 1996;334:763-8.
42. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95: 1777-82.
43. Martinelli I, Cattaneo M, Panzeri D, et al. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997;77:440-3.
44. Manten B, Westendorp RG, Koster T, et al. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost 1996;76:510-3.
45. Giuntini C, Di Ricco G, Marini C, et al. Epidemiology. Chest 1995;107:3S-9S.
46. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
47. Quinn DA, Thompson T, Terrin ML, et al. A prospective investigation of pulmonary embolism in women and men. JAMA 1992;268:1689-96.
48. WHO Collaborative Study. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82.
49. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983-7.
50. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Azrg506 >Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403.